Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-14

couldn't agree more on Cann..another CR coming up but all in the hope that Cann is able to get S3 registration and deal with Haleon. trial expected to complete in Q1 2023 followed by TGA registration. ceo also leaving the company which will give opportunity to bring someone with pharma background to lead the next phase of growth... while not ideal, there seems to be some actions in Cann...

As for MDC, MD gets paid >$600k pa for some reason which is always questionable for the size and operation of the company, who knows what's happening with nanocelle..nanabis p3 can't go ahead till funding is in place, US listing delayed because of pre-listing due diligence gaps...the only consistent action in MDC is reallocation of funds from MDC bank account to mngt and BoD account..good luck
Dyor imo